Selective HDAC3 inhibitors

• US 9,139,583 B2
• Filed: 01/31/2014
• Issued: 09/22/2015
• Est. Priority Date: 02/01/2013
• Status: Active Grant

• Current Assignee: Regenacy Pharmaceuticals LLC
• Original Assignee: Acetylon Pharmaceuticals, Inc. (Bristol-Myers Squibb Company)
• Inventors: van Duzer, John H., Mazitschek, Ralph
• Primary Examiner(s): Jackson, Shawquia
• Application Number:
  US14/169,775
• Publication Number:
  US 20140249148A1
• Time in Patent Office: 599 Days
• Field of Search: 548/484, 548/304.4, 544/140, 544/141
• US Class Current: 1/1
• CPC Class Codes: C07D 209/34 in position 2
• CPC Class Codes: C07D 215/54 attached in position 3
• CPC Class Codes: C07D 231/56 Benzopyrazoles; Hydrogenated benzopyrazoles
• CPC Class Codes: C07D 235/06 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

Provided herein are inhibitors of HDAC3, as well as methods of treatment comprising administering those compounds to a subject in need thereof.

Claims

1. A compound selected from the following:

2. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

3. A method of treating type 2 diabetes, Huntington'"'"'s disease, spinal and bulbar muscular atrophy, or lung cancer in a subject comprising administering to the subject a compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. The method of claim 3, wherein the disease is type 2 diabetes.

5. The method of claim 3, wherein the disease is Huntington'"'"'s disease.

6. The method of claim 3, wherein the disease is spinal and bulbar muscular atrophy.

7. The method of claim 3 wherein the disease is lung cancer.

8. The method of claim 3, wherein the subject is human.

9. A compound which is:

10. A compound which is:

11. A compound which is: